A phase I/II study of Bevacizumab combined with Cisplatin and Pemetrexed for Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer
- Conditions
- non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000004118
- Lead Sponsor
- Hamamatsu University School of Medicine, First Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 82
Not provided
1) squamous cell carcinoma 2) Patients unable to take or unsupplied with folic acid and vitamin B12 3) History of grave drug allergic react 4) current or previous histoty of hemoptysis (2.5ml) due to NSCLC 5) Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray 6) Brain metastases with neurological symptoms 7) Pleural effusion, pericardial effusion and ascites to need treatment 8) Severe renal function disorder, 2+ or higher proteinuria within 2 weeks prior to enrollment 9) Uncontrollable diabetes mellitus and hypertenson 10) severe cardiac disease 11) Current or previous history of cerebrovascular disease 12) Current of amalgamated venous thromboembolism 13) Uncontrollable infectious disease 14) current or previous (within the last 1 year) history of GI perforation 15) Traumatic fracture of unrecovery 16) active concomitant malignancy 17) Thoracic radiotherapy has been scheduled for the examination period 18) Surgical procedure within 28 days before registration 19) history of pregnancy or lactation 20) No intention to practice birth control 21) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method